Zartler Edward R, Shapiro Michael J
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USA.
Curr Opin Chem Biol. 2005 Aug;9(4):366-70. doi: 10.1016/j.cbpa.2005.05.002.
The use of smaller molecules (fragments) in the drug discovery process has led to success in delivering novel leads for many different targets. This process is a highly integrated process, starting from library design to screening and medicinal chemistry. An overview of this process is presented with particular emphasis placed on the NMR aspect of screening.
在药物发现过程中使用小分子（片段）已成功为许多不同靶点提供了新的先导化合物。这个过程是一个高度整合的过程，从文库设计到筛选以及药物化学。本文对这一过程进行了概述，特别强调了筛选的核磁共振方面。
